CoChat

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Open access

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Treatment with a frontline BCR-ABL1 tyrosine kinase inhibitor (TKI; e.g., imatinib, dasatinib, and nilotinib) allows patients with chronic myeloid leukemia (CML) in chronic phase (CP) to achieve a near normal life expectancy 1 , whereas treatment for CML in accelerated phase (AP) is more problematic. While reports describe outcomes for patients with CML-AP at initial diagnosis 2 , 3 , outcomes have been historically worse once CP disease has progressed to AP. Approximately 50% of patients with CML-AP who receive imatinib as initial treatment develop imatinib resistance 4 and experience disease progression 5 . Second-generation TKIs are indicated for patients with CML-CP or advanced CML resistant to/intolerant of prior therapy (including imatinib) 6 . After initial approval of dasatinib twice a day (BID) for the treatment of patients with CML resistant to/intolerant of imatinib in all stages, this phase 3 CA180-035 study (NCT00123487) was developed to investigate once (QD) or twice (BID) a day dasatinib treatment in patients with CML-AP, CML in blast phase, or Ph+ acute lymphoblastic leukemia resistant to/intolerant of imatinib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41408-018-0122-3

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Efficacy outcomes for patients with CML-AP by dosing schedule. a Duration of MaHR for patients who achieved MaHR, b PFS, and c OS are shown for the QD (solid lines) and BID (dashed lines) dosing groups. Efficacy analyses were conducted in the intention-to-treat population of patients. BID twice a day, CI confidence interval, MaHR major hematologic response, NA not available, OS overall survival, PFS progression-free survival, QD once a day
Fig. 1 Efficacy outcomes for patients with CML-AP by dosing schedule. a Duration of MaHR for patients who achieved MaHR, b PFS, and c OS are shown for the QD (solid lines) and BID (dashed lines) dosing groups. Efficacy analyses were conducted in the intention-to-treat population of patients. BID twice a day, CI confidence interval, MaHR major hematologic response, NA not available, OS overall survival, PFS progression-free survival, QD once a dayCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 30

Metadata

Authors
Ottmann, O., Saglio, G., Apperley, J. F., Arthur, C., Bullorsky, E., Charbonnier, A., Dipersio, J. F., Kantarjian, H., Khoury, H. J., Kim, D.-W., Healey, D., Strauss, L., & Cortes, J. E.
Affiliations
  • Cardiff University (GB)
  • University of Turin (IT)
  • Imperial College London (GB)
  • Royal North Shore Hospital (AU)
  • Hospital Británico de Buenos Aires (AR)
  • Institut Paoli-Calmettes (FR)
  • Washington University in St. Louis (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Emory University (US)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
Ottmann, Oliver
Venue
Blood Cancer Journal
Published
2018-09-03
Volume
8
Issue
9
Pages
88-88
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2892098229
Cited by
30
References
8
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 5 · 2019: 1
FWCI
1.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Blood Cancer Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Bristol-Myers Squibb
  • National Institute for Health and Care Research (NF-SI-0617-10126, NF-SI-0611-10275)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
dasatinib, chronic myeloid leukemia, accelerated phase, imatinib resistance, imatinib intolerance, BCR-ABL tyrosine kinase inhibitors, once-daily dosing, twice-daily dosing, long-term efficacy, drug safety
MeSH terms
Imatinib Mesylate, Dasatinib, Antineoplastic Agents, Humans, Neoplasm Staging, Leukemia, Myeloid, Accelerated Phase, Randomized Controlled Trials as Topic, Treatment Outcome, Drug Resistance, Neoplasm, Retreatment, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. https://app.cochat.ai/papers/10.1038/s41408-018-0122-3
The paper
Ottmann, O., Saglio, G., Apperley, J. F., Arthur, C., Bullorsky, E., Charbonnier, A., Dipersio, J. F., Kantarjian, H., Khoury, H. J., Kim, D.-W., Healey, D., Strauss, L., & Cortes, J. E. (2018). Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal. https://doi.org/10.1038/s41408-018-0122-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.